WHO Reports Continued Increase in Antibiotic-Resistant Gonorrhea — Physician’s First Watch

Medical News |
July 10, 2017

WHO Reports Continued Increase in Antibiotic-Resistant Gonorrhea

By Amy Orciari Herman

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

Gonorrhea resistant to last-resort antibiotics has been found in two-thirds of countries with available data, the World Health Organization said on Friday.

Analyzing 2009–2014 data from the WHO Global Gonococcal Antimicrobial Surveillance Programme, the agency found that 97% of countries reported strains resistant to ciprofloxacin, 81% had strains resistant to azithromycin, and 66% (more than 50 countries) reported strains resistant to oral cefixime or injectable ceftriaxone, considered to be last-resort treatments.

Because of increasing resistance, the WHO in 2016 recommended dual therapy with ceftriaxone and azithromycin over single drug therapy.

The research and development pipeline for new gonorrhea drugs is "relatively empty," the WHO says. As such, the Global Antibiotic Research and Development Partnership has made new gonorrhea treatments a top priority. In addition, the WHO stresses the need for accurate, rapid diagnostic tests, and emphasizes the importance of gonorrhea prevention.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.